New Zealand markets closed

Hillstream BioPharma, Inc. (HILS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2305+0.0062 (+2.76%)
At close: 03:59PM EDT
0.2399 +0.01 (+4.08%)
After hours: 07:27PM EDT

Hillstream BioPharma, Inc.

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807
United States
908 955 3140

Full-time employees1

Key executives

NameTitlePayExercisedYear born
Mr. Randy D. Milby MBAPres, Chairman & CEO471.94kN/A1954
Mr. Sireesh Appajosyula Pharm.D.COO & Director64.96kN/A1976
Mr. Thomas P. Hess CPA, MBAChief Financial OfficerN/AN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Corporate governance

Hillstream BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.